Patient characteristics and BCRP and MDR1 mRNA expression, listed in order of BCRP expression
Patient . | Age, y* . | Sex . | Ethnicity . | Marrow or PB . | FAB . | Cytogenetics . | Immunophenotype . | Disease status† . | Response to Rx‡ . | % Blasts cytospin1-153 . | mRNA expression relative to MCF-7 or HL-60 . | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
BCRP1-155 . | MDR11-154 . | |||||||||||
17 | 61 | F | W | PB | M5 | 46,XX,−5,−7, +8, 11q23 | CD2, 7, 11c, 14 (partial), 33, 38, 45 | New | NR | 95 | 0.002 | 0.702 |
1 | 40 | M | W | BM | M5 | 46,XY | CD11c, 13, 33, 34, 36, DR | Rel | NR | 98 | 0.01 | — |
6 | 43 | M | W | BM | M2 | 46,XY | CD13, 33, 34, DR | New | CR | 88 | 0.01 | — |
8 | 33 | M | W | BM | M2 | 45X, −Y, t(8;21) | CD33, 34, DR | New | CR-S | 98 | 0.01 | — |
9 | 55 | F | A | PB | M1 | 46,XX | CD13, 33, 45, DR | New | CR-S | 95 | 0.01 | — |
14b | 27 | M | W | BM | M4eos | 46,XY, (inv)16 (p13q22) | CD13, 33, 34 | Rel | CR | 98 | 0.01 | 0.142 |
19 | 77 | F | W | BM | M1 | 46,XX | CD7, 11c, 13, 33, 34 (partial), 38, 45, DR | Rel | NE | 91 | 0.017 | 0.413 |
10 | 55 | M | W | PB | M1 | 46,XY, −13q12-22, −1q32 | CD13, 33, 38 | New | CR-S | 98 | 0.02 | — |
13 | 29 | M | W | BM | M2 | 47,XY, +8 | CD13, 33 | New | NR | 90 | 0.02 | — |
11 | 67 | M | W | BM | M1 (2°) | 47,XY, +13 | CD13, 33, 34, DR | Rel | NR | 81 | 0.04 | — |
14a | 23 | M | W | BM | M4eos | 46,XY, (inv)16 (p13q22) | CD13, 33, 34 | New | CR | 98 | 0.05 | — |
2 | 62 | M | W | PB | M5 | 46,XY, t(3;5) | CD11c, 13, 14, 33, 38, DR | New | NR | 98 | 0.06 | 0.322 |
12 | 77 | F | Other | BM | M1 | Not done | Not done | New | CR-S | 80 | 0.08 | — |
18 | 67 | M | W | BM | M1 (MDS) | 46,XY | CD13, 33 (dim), 34, 35, DR | Rel | NR | 91 | 0.168 | 3.123 |
20 | 49 | M | W | BM | M1 | 46,XY | CD13, 33, 34, 38, 45, DR | Rel | CR | 88 | 0.198 | 3.291 |
21 | 21 | M | W | PB | ALL (L2) | Not done | Not done | Rel | NR | 97 | 0.315 | 3.617 |
4 | 30 | M | B | BM | M4 | 45,XY, −7 | CD11C, 13, 14, 33, 38, DR | New | CR-S | 80 | 0.33 | — |
7 | 56 | F | W | BM | M0 (MDS) | 46,XX t(X;12) | CD7, 33, 34, 45(dim), DR | New | NR | 93 | 0.35 | — |
5 | 63 | M | W | BM | M1 | 46,XY, −2p16 | CD13, 33, 34, 38, DR | New | NR | 94 | 0.36 | — |
15 | 59 | M | W | BM | M0 | 46,XY | CD2, 16/56, 7, 33, 38, 45, DR | Partial response | CR | 80 | 0.616 | 2.432 |
16 | 72 | F | W | BM | M4 (2°) | 46,XX | CD13 (dim), 16/56, 33, 38, DR | New | NR | 88 | 0.675 | 0.955 |
3 | 72 | F | B | BM | M6 | 45,XX, −3, −4, −5, −7, +8, −11, −17, −18, −19, 3 markers | Not done | New | NR | 82 | 2.59 | — |
Patient . | Age, y* . | Sex . | Ethnicity . | Marrow or PB . | FAB . | Cytogenetics . | Immunophenotype . | Disease status† . | Response to Rx‡ . | % Blasts cytospin1-153 . | mRNA expression relative to MCF-7 or HL-60 . | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
BCRP1-155 . | MDR11-154 . | |||||||||||
17 | 61 | F | W | PB | M5 | 46,XX,−5,−7, +8, 11q23 | CD2, 7, 11c, 14 (partial), 33, 38, 45 | New | NR | 95 | 0.002 | 0.702 |
1 | 40 | M | W | BM | M5 | 46,XY | CD11c, 13, 33, 34, 36, DR | Rel | NR | 98 | 0.01 | — |
6 | 43 | M | W | BM | M2 | 46,XY | CD13, 33, 34, DR | New | CR | 88 | 0.01 | — |
8 | 33 | M | W | BM | M2 | 45X, −Y, t(8;21) | CD33, 34, DR | New | CR-S | 98 | 0.01 | — |
9 | 55 | F | A | PB | M1 | 46,XX | CD13, 33, 45, DR | New | CR-S | 95 | 0.01 | — |
14b | 27 | M | W | BM | M4eos | 46,XY, (inv)16 (p13q22) | CD13, 33, 34 | Rel | CR | 98 | 0.01 | 0.142 |
19 | 77 | F | W | BM | M1 | 46,XX | CD7, 11c, 13, 33, 34 (partial), 38, 45, DR | Rel | NE | 91 | 0.017 | 0.413 |
10 | 55 | M | W | PB | M1 | 46,XY, −13q12-22, −1q32 | CD13, 33, 38 | New | CR-S | 98 | 0.02 | — |
13 | 29 | M | W | BM | M2 | 47,XY, +8 | CD13, 33 | New | NR | 90 | 0.02 | — |
11 | 67 | M | W | BM | M1 (2°) | 47,XY, +13 | CD13, 33, 34, DR | Rel | NR | 81 | 0.04 | — |
14a | 23 | M | W | BM | M4eos | 46,XY, (inv)16 (p13q22) | CD13, 33, 34 | New | CR | 98 | 0.05 | — |
2 | 62 | M | W | PB | M5 | 46,XY, t(3;5) | CD11c, 13, 14, 33, 38, DR | New | NR | 98 | 0.06 | 0.322 |
12 | 77 | F | Other | BM | M1 | Not done | Not done | New | CR-S | 80 | 0.08 | — |
18 | 67 | M | W | BM | M1 (MDS) | 46,XY | CD13, 33 (dim), 34, 35, DR | Rel | NR | 91 | 0.168 | 3.123 |
20 | 49 | M | W | BM | M1 | 46,XY | CD13, 33, 34, 38, 45, DR | Rel | CR | 88 | 0.198 | 3.291 |
21 | 21 | M | W | PB | ALL (L2) | Not done | Not done | Rel | NR | 97 | 0.315 | 3.617 |
4 | 30 | M | B | BM | M4 | 45,XY, −7 | CD11C, 13, 14, 33, 38, DR | New | CR-S | 80 | 0.33 | — |
7 | 56 | F | W | BM | M0 (MDS) | 46,XX t(X;12) | CD7, 33, 34, 45(dim), DR | New | NR | 93 | 0.35 | — |
5 | 63 | M | W | BM | M1 | 46,XY, −2p16 | CD13, 33, 34, 38, DR | New | NR | 94 | 0.36 | — |
15 | 59 | M | W | BM | M0 | 46,XY | CD2, 16/56, 7, 33, 38, 45, DR | Partial response | CR | 80 | 0.616 | 2.432 |
16 | 72 | F | W | BM | M4 (2°) | 46,XX | CD13 (dim), 16/56, 33, 38, DR | New | NR | 88 | 0.675 | 0.955 |
3 | 72 | F | B | BM | M6 | 45,XX, −3, −4, −5, −7, +8, −11, −17, −18, −19, 3 markers | Not done | New | NR | 82 | 2.59 | — |
PB indicates peripheral blood; FAB, French, American, and British classification of acute leukemia; F, female; W, white; new, newly diagnosed, untreated; NR, no response; M, male; BM, bone marrow; Rel, in relapse; CR, durable complete remission (>8 mo), CR-S, short remission (<8 mo); A, Asian; NE, not evaluable; B, black.
Median = 55.5 y.
At time of blast cell sampling for BCRP studies.
Response to subsequent treatment.
Median = 92.
Expression of BCRP mRNA relative to that of MCF-7 cells, after correction for the expression of β-actin.
Expression of MDR1 mRNA relative to that of HL-60/Vinc cells (×10−7) after correction for the expression of β-actin.